Diakonhjemmet Hospital
Oslo, 0319, Norway
NCT Number: NCT06211322
In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
Oslo, 0319, Norway
In this feasibility study various outcome measures will be assessed to determine whether the app (Urika) is viable, practical, and useful. The study will include assessments of technical, operational, clinical, and trial aspects of feasibility.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
Time frame: Through study completion, an average of 3 months
Acceptable overall feasibility of the app with ≥70% of the secondary endpoints indicating feasibility.
Time frame: Through study completion, an average of 3 months
Acceptable number of errors (≤5 errors per participant) in the performance and functionality experienced by the patients and project group members
Time frame: At 3 months
Considered feasible if the System Usability Scale median score is ≥68 on a 0-100 scale, 100= best score
Time frame: At 3 months
Open responses will be collected in semi-structured interview. No scales or instruments will be used
Time frame: Pre-baseline for health professionals and at baseline for patients
Measured by registering amount of time spent (minutes) on training
Time frame: At 3 months
Measured by a numeric rating scale (NRS) 0-10, higher scores mean better outcome. Acceptable feasibility if >=70% of the participants report score >=5, otherwise considered not acceptable feasibility.
Time frame: At screening and enrollment
Measured by registering time spent on screening and enrollment
Time frame: At 3 months
Considered feasible if there is available data on serum urate levels for ≥90% of patients for calculation of mean levels and proportion with low serum urate level
Time frame: Through study completion, an average of 3 months
Total number of reported errors related to the software functionality (e.g., downloading, login, registration of medication, reminders, access to videos, medication adherence, registration of blood test results, urate level graph, blood test history, chat, request new prescription). Considered acceptable feasibility if the number of errors are ≤5 per patient in the performance and functionality experienced by the patients and project group members.
Time frame: Through study completion, an average of 3 months
Considered feasible if patient-reported data and the medication history in the app monitored in the platform for health personnel is available for ≥90% of patients.
Time frame: At 3 months
Patient-reported Medication Adherence Report Scale (MARS-5), score range 5-25, higher scores mean better adherence. Considered acceptable feasibility if >=90% of the patients complete the instrument.
Time frame: At 3 months
Number of acute gout flares
Time frame: At 3 months
Number of side-effects registered in the app or by study nurse or study coordinator
Time frame: At 3 months
Number of adverse events (incl. serious adverse events) registered by study medical doctor, study nurse or study coordinator
Time frame: At 3 months
Measured by a single item with 5 response categories, ranging from very dissatisfied to very satisfied, higher scores mean higher satisfaction. Considered acceptable feasibility if >=70% of the participants report to be satisfied or very satisfied.
Time frame: At baseline and 3 months
Measured by the Gout Knowledge Questionnaire, 0-10, higher scores mean better outcome. Considered acceptable feasibility if there is available total score data for >=90% of the patients.
Time frame: At 3 months
Measured by a numeric rating scale (NRS) 0-10, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.
Time frame: At 3 months
Measured by the Euro Quality of Life 5 Dimensions 5 Levels, each item is scored 1-5, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.
Time frame: At 3 months
Measured by Work Productivity and Activity Impairment (WPAI) item no.6, 0-10, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.
Time frame: At 3 months
Considered acceptable feasibility if there is available data for ≥90% of patients on patient-reported visits in specialist or primary healthcare
Time frame: At 3 months
Considered acceptable feasibility if there is available data for ≥90% of patients on patient-reported time for travelling to the hospital
Time frame: At 3 months
Considered acceptable feasibility if there is available data for ≥90% of participants using self-report
Time frame: At enrollment
Number of eligible patients per month.
Time frame: After enrollment
Acceptable recruitment rate is ≥50% of eligible patients.
Time frame: At 3 months
Number of patients that withdraw from the study. Acceptable withdrawal rate is ≤20% of included patients.
Time frame: At 3 months
Acceptable overall trial logistics (Identification, screening, recruitment, patient training, data collections, monitoring blood test results, renewal of prescriptions) evaluated as Yes vs. No by the study group.
Time frame: Through study completion, an average of 3 months
Count the number of videos watched per participant. Considered acceptable feasibility if ≥70% of the participants have watched at least 1 video.
Time frame: Through study completion, an average of 3 months
Count the number of registrations of daily medication adherence. Considered acceptable feasibility if ≥70% of the participants have registered at least 1 adherence.
Time frame: Through study completion, an average of 3 months
Count the number of registered serum urate levels. Considered acceptable feasibility if ≥90% of the patients register their serum urate level monthly.
Time frame: Through study completion, an average of 3 months
Count the number of chat messages. Considered acceptable feasibility if ≥70% of the participants register at least 1 chat message.
Time frame: Through study completion, an average of 3 months
Count the number of flare registering. Considered acceptable feasibility if ≥10% of the participants register 1 flare.
Time frame: At 3 months
Incidence of hinders that could harm a successful clinical evaluation of the app in a large randomised, controlled trial.
Diakonhjemmet Hospital
Other
The ReMonit Gout Feasibility Study
Acronym: ReMonit Gout
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05499312
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shatin, Hong Kong
View Trial DetailsNCT05665699
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06229145
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06969469
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Taipei, Taiwan
View Trial Details